The Asia Pacific Cell-based Assays Market would witness market growth of 9.0% CAGR during the forecast period (2022-2028).
ROS stands for reactive oxygen species, which refers to oxygen-containing molecules that exhibit chemical reactivity. ROS assays can be employed to screen chemical compounds, determine the effects of certain species on mammalian cells, and gain a better understanding of these effects. One of the most important distinctions between cell-based assays and biochemical assays is that cell-based ROS as well as oxidative stress assays offer biologically relevant data to evaluate cell viability, proliferation, or cytotoxicity.
This is in contrast to biochemical assays, which measure the binding or activity of biological molecules. Protein concentration can be measured using different types of protein assays. The enzyme-linked immunosorbent assay, which is used to determine and quantify soluble substances for medical testing and quality control, and the MTT assay, which is used to quantify cellular metabolic activity as an indicator of cell viability, proliferation, and cytotoxicity, are both examples of common protein assays.
It is essential to consider the development and deployment of translational phenotypic assays in addition to the deciphering of various molecular mechanisms of action for novel molecular entities if one aims to limit the amount of attrition that occurs during the drug development process. Through a method that is now known as high-content screening, high-throughput fluorescence as well as confocal microscopes with advanced analytical software have made it easier to simultaneously identify and quantify a wide variety of cellular processes. This method was formerly known as high-content imaging (HCS).
The Indian pharmaceutical industry, with a wide prevalence of several key market players, is expanding at an exponential rate. In the early 1990s, India announced that it had signed an agreement with the World Trade Organization that would begin implementing a product patent system in 2005. This announcement marked the beginning of Indian pharmaceutical companies' entry into the field of drug discovery and development. Alterations to the regulatory environment in the same year led to other developments, such as the emergence of the country as a favourite destination for chemistry outsourcing, followed by collaborative drug discovery as contract authorities where in-house capabilities in the chemistry of local companies were augmented with focus biology.
The China market dominated the Asia Pacific Cell-based Assays Market by Country in 2021; thereby, achieving a market value of $1.8 billion by 2028. The Japan market is registering CAGR of 8.4% during (2022 - 2028). Additionally, The India market would showcase a CAGR of 9.7% during (2022 - 2028).
Based on Application, the market is segmented into Drug Discovery, Basic Research and Others. Based on End User, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Research Institutes and Contract Research Organizations (CROs). Based on Products & Services, the market is segmented into Assay Kits, Reagents, Microplates, Probes & Labels, Instruments & Software and Cell Lines. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Cell-based Assays Market is Projected to reach USD 24.9 Billion by 2028, at a CAGR of 8.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Corning Incorporated, Charles River Laboratories International, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Lonza Group AG, Merck Group, Promega Corporation and Thermo Fisher Scientific, Inc.
By Application
By End User
By Products & Services
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
